Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.

about

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

P2860

Q55693561-E4506C49-3AF5-4379-B0AE-D8247D57FB30

P2860

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.

Item

http://www.wikidata.org/entity/Q48282663

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Long-term efficacy and safety ...... nts: a multicentre experience.

@en

Long-term efficacy and safety ...... nts: a multicentre experience.

@nl

type

Item

label

Long-term efficacy and safety ...... nts: a multicentre experience.

@en

Long-term efficacy and safety ...... nts: a multicentre experience.

@nl

prefLabel

Long-term efficacy and safety ...... nts: a multicentre experience.

@en

Long-term efficacy and safety ...... nts: a multicentre experience.

@nl

P1476

Long-term efficacy and safety ...... ents: a multicentre experience

@en

P2093

A Bourrier

http://www.w3.org/2001/XMLSchema#string

B Coffin

http://www.w3.org/2001/XMLSchema#string

B Duclos

http://www.w3.org/2001/XMLSchema#string

Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)

http://www.w3.org/2001/XMLSchema#string

H Brixi

http://www.w3.org/2001/XMLSchema#string

J Filippi

http://www.w3.org/2001/XMLSchema#string

M Allez

http://www.w3.org/2001/XMLSchema#string

M Fumery

http://www.w3.org/2001/XMLSchema#string

M Serrero

http://www.w3.org/2001/XMLSchema#string

M Simon

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement

Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health.

Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.

Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.

Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience.

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.

P304

588-595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/APT.14487

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29315694

http://www.w3.org/2001/XMLSchema#string

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.

about

P2860

P2860

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698